Compounds, compositions, methods, and kits relating to telomere extension

Patent metadata

Field	Value
Publication number	US-11872243-B2
Application number	US-202016735683-A
Country	US
Kind code	B2
Filing date	Jan 6, 2020
Priority date	Feb 22, 2013
Publication date	Jan 16, 2024
Grant date	Jan 16, 2024

Abstract

Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

First claim

What is claimed is:

1. A method of treating an animal subject, comprising:
administering a compound to the animal subject,
wherein the compound comprises a synthetic ribonucleic acid comprising at least one modified nucleoside and coding for a telomerase reverse transcriptase,
wherein the animal subject suffers from or is at risk of a disease resulting from shortened telomeres; and
wherein at least one telomere is extended within a cell in the animal subject.

2. The method of claim 1 , wherein the disease is selected from the group consisting of metabolic syndrome, diabetes, diabetic ulcers, heart disease, cancer, vascular dementia, Alzheimer's disease, stroke, age-related macular degeneration, immunosenescence, bone marrow failure, gastrointestinal ulcers, cirrhosis, hernia, infection, chronic infection, mild or severe cognitive impairment, impaired mobility, osteoporosis, osteoarthritis, rheumatoid arthritis, age-related anxiety, balance disorders, tinnitus, Bell's palsy, cataracts, chronic obstructive pulmonary disease, corneal abrasion, coronary artery disease, peripheral artery disease, conjunctivitis, chalazion, dehydration, depression, emphysema, eye disease, failure to thrive, flu, generalized anxiety disorder, glaucoma, hearing loss, loss of sense of taste, loss of appetite, hip dislocation, memory loss, Parkinson's disease, spinal stenosis, urinary incontinence, and vertebral fracture.

3. The method of claim 1 , wherein the animal subject suffers from or is at risk of an age-related illness, an age-related condition, or an age-related decline in function or appearance.

4. The method of claim 1 , further comprising the step of:
measuring telomere length of a cell in or from the subject animal and administering the compound if a shortened telomere length is detected.

5. The method of claim 4 , wherein the measuring and administering steps are repeated at least once.

6. The method of claim 1 , wherein the at least one telomere is transiently extended within the cell of the subject animal.

7. The method of claim 1 , comprising:
administering a composition to the animal subject;
wherein the composition comprises the compound of claim 1 ; and
a telomerase RNA component, a delivery vehicle, or both a telomerase RNA component and a delivery vehicle.

8. The method of claim 7 , wherein the telomerase RNA component is a mammalian, avian, reptilian, or fish telomerase RNA component.

9. The method of claim 8 , wherein the telomerase RNA component is a human telomerase RNA component.

10. The method of claim 7 , wherein the delivery vehicle is an exosome, a lipid nanoparticle, a polymeric nanoparticle, a natural or artificial lipoprotein particle, a cationic lipid, a protein, a protein-nucleic acid complex, a liposome, a virosome, or a polymer.

11. The method of claim 10 , wherein the delivery vehicle is a cationic lipid.

12. The method of claim 11 , wherein the delivery vehicle is non-immunogenic.

13. The method of claim 1 , wherein the telomerase reverse transcriptase is a mammalian, avian, reptilian, or fish telomerase reverse transcriptase or a variant that retains telomerase catalytic activity.

14. The method of claim 13 , wherein the telomerase reverse transcriptase is a human telomerase reverse transcriptase.

15. The method of claim 1 , wherein the ribonucleic acid comprises a 5′ cap, a 5′ untranslated region, a 3′ untranslated region, and a poly-A tail.

16. The method of claim 15 , wherein the 5′ cap is non-immunogenic.

17. The method of claim 15 , wherein the 5′ cap has been treated with phosphatase.

18. The method of claim 15 , wherein the poly-A tail increases stability of the ribonucleic acid.

19. The method of claim 15 , wherein the 5′ untranslated region or the 3′ untranslated region comprise a sequence from a stable mRNA or an mRNA that is efficiently translated.

20. The method of claim 15 , wherein the 5′ untranslated region and the 3′ untranslated region both comprise a sequence from a stable mRNA or an mRNA that is efficiently translated.

21. The method of claim 15 , wherein the 5′ cap, the 5′ untranslated region, or the 3′ untranslated region stabilizes the ribonucleic acid, increases the rate of translation of the ribonucleic acid, or modulates the immunogenicity of the ribonucleic acid.

22. The method of claim 1 , wherein the at least one modified nucleoside modulates immunogenicity of the ribonucleic acid.

23. The method of claim 1 , wherein the synthetic ribonucleic acid is a purified synthetic ribonucleic acid.

24. The method of claim 23 , wherein the synthetic ribonucleic acid is purified to remove immunogenic components.

25. The method of claim 1 , wherein the ribonucleic acid codes for a human, cat, dog, mouse, horse, cow, sheep, pig, African elephant, chicken, rat, zebrafish, Japanese medaka, or chimpanzee telomerase reverse transcriptase, or a polypeptide with at least 95% sequence identity to the telomerase reverse transcriptase.

26. The method of claim 25 , wherein the ribonucleic acid codes for a human telomerase reverse transcriptase, or a polypeptide with at least 95% sequence identity to the human telomerase reverse transcriptase.

27. The method of claim 1 , wherein the animal subject is a mammal.

28. The method of claim 27 , wherein the animal subject is a human.

Assignees

• Univ Leland Stanford Junior

Inventors

• Ramunas John
• Yakubov Eduard
• Blau Helen M
• Cooke John

Classifications

• A61K31/7088 Primary

  Compounds having three or more nucleosides or nucleotides · CPC title

• A61K38/45

  Transferases (2) · CPC title

• C12N9/1276

  RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase · CPC title

• C12N15/52

  Genes encoding for enzymes or proenzymes · CPC title

• C12Y207/07049

  RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase · CPC title